-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
-
All patients admitted to the ICU at the Air Force Theater Hospital (Balad, Iraq) were followed prospectively for the development of VAP. There were 475 patients admitted to the ICU from May 2006 through August 2006.
-
The utility of surveillance screening for MRSA on hospital admission remains controversial. Three recently published clinical trials attempt to assess the role of MRSA surveillance.
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
The FDA has approved Relistor (methylnaltrexone bromide) to help restore bowel function in patients with late-stage, advanced illness who are receiving opioids on a continuous basis to help alleviate their pain.
-
A hospital's drug information call center fielded numerous phone calls about finding forms and regulatory or accreditation requirements. While the call center experts were happy to help out it took up a lot of time they could have been spending on more vital questions about medications.
-
Hospital pharmacists increasingly are pressed for time, and the trick for pharmacy managers is to find ways to improve quality and safety while improving staff efficiency.
-
-
The human immunodeficiency virus (HIV) is the biological cause of the acquired immunodeficiency syndrome (AIDS), which was first recognized in the United States in 1981.
